We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eni S.p.A. (E - Free Report) is strengthening its chemicals business through an expanded collaboration between its subsidiary Versalis and Lummus Technology, aimed at extending the global reach of its proprietary technologies. The agreement adds Versalis' elastomer technologies to the existing partnership, more than doubling the technology portfolio available for licensing.
Under the arrangement, Lummus will serve as the exclusive licensor, leveraging its international commercial network to market these technologies worldwide. The expansion is expected to create new opportunities for E to commercialize its chemical expertise across international markets.
The expanded partnership combines Versalis' expertise in elastomer production with Lummus' engineering capabilities to provide customers with integrated solutions spanning feedstock processing to finished polymers. Both companies will collaborate on engineering, technology development, equipment supply and technical support, strengthening their ability to serve chemical producers.
By combining elastomer technologies with existing butadiene and styrene offerings, the partnership aims to deliver more integrated and flexible production solutions. This broader offering may help Versalis attract additional licensing opportunities and strengthen its position in international chemical technology markets.
For Eni, the agreement supports Versalis' ongoing transformation toward specialized, higher-value chemical activities while expanding the commercial reach of its proprietary technologies. The agreement is expected to enhance Eni's chemicals portfolio, broaden its licensing opportunities and support future growth through international expansion.
XOM & SHEL Focus on Chemical Business Growth
ExxonMobil Holdings Corporation (XOM - Free Report) and Shell plc (SHEL - Free Report) are strengthening their chemicals businesses through operational improvements, higher-value products and investments aimed at improving profitability.
ExxonMobil reported third-quarter 2026 Chemical Products earnings of $735 million, up from $515 million in the year-ago quarter, supported by stronger North American feedstock advantages and structural cost savings. The company benefited from record operational reliability, while higher sales of premium chemical products supported its business despite weaker sequential margins. XOM continues to focus on manufacturing efficiency and high-value products to strengthen its chemicals portfolio and long-term earnings potential.
Shell reported third-quarter 2026 Chemicals adjusted earnings of $103 million, while chemical sales volumes rose to 2.37 million tons from 2.28 million tons in the prior quarter. The company improved chemical plant utilization to 84% from 83%, reflecting reduced maintenance activities. SHEL expects fourth-quarter 2026 chemical plant utilization of 78-86%, highlighting its continued focus on operational performance amid challenging chemical market conditions.
E’s Price Performance, Valuation & Estimates
Eni shares have gained 43.1% over the past year compared with the industry’s 35.4% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, E trades at a trailing 12-month enterprise-value-to-EBITDA (EV/EBITDA) of 6.84X. This is higher than the broader industry average of 5.35X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for E's 2026 earnings has remained constant over the past seven days.
Image: Bigstock
Will Eni's Expanded Lummus Partnership Boost Chemical Growth?
Key Takeaways
Eni S.p.A. (E - Free Report) is strengthening its chemicals business through an expanded collaboration between its subsidiary Versalis and Lummus Technology, aimed at extending the global reach of its proprietary technologies. The agreement adds Versalis' elastomer technologies to the existing partnership, more than doubling the technology portfolio available for licensing.
Under the arrangement, Lummus will serve as the exclusive licensor, leveraging its international commercial network to market these technologies worldwide. The expansion is expected to create new opportunities for E to commercialize its chemical expertise across international markets.
The expanded partnership combines Versalis' expertise in elastomer production with Lummus' engineering capabilities to provide customers with integrated solutions spanning feedstock processing to finished polymers. Both companies will collaborate on engineering, technology development, equipment supply and technical support, strengthening their ability to serve chemical producers.
By combining elastomer technologies with existing butadiene and styrene offerings, the partnership aims to deliver more integrated and flexible production solutions. This broader offering may help Versalis attract additional licensing opportunities and strengthen its position in international chemical technology markets.
For Eni, the agreement supports Versalis' ongoing transformation toward specialized, higher-value chemical activities while expanding the commercial reach of its proprietary technologies. The agreement is expected to enhance Eni's chemicals portfolio, broaden its licensing opportunities and support future growth through international expansion.
XOM & SHEL Focus on Chemical Business Growth
ExxonMobil Holdings Corporation (XOM - Free Report) and Shell plc (SHEL - Free Report) are strengthening their chemicals businesses through operational improvements, higher-value products and investments aimed at improving profitability.
ExxonMobil reported third-quarter 2026 Chemical Products earnings of $735 million, up from $515 million in the year-ago quarter, supported by stronger North American feedstock advantages and structural cost savings. The company benefited from record operational reliability, while higher sales of premium chemical products supported its business despite weaker sequential margins. XOM continues to focus on manufacturing efficiency and high-value products to strengthen its chemicals portfolio and long-term earnings potential.
Shell reported third-quarter 2026 Chemicals adjusted earnings of $103 million, while chemical sales volumes rose to 2.37 million tons from 2.28 million tons in the prior quarter. The company improved chemical plant utilization to 84% from 83%, reflecting reduced maintenance activities. SHEL expects fourth-quarter 2026 chemical plant utilization of 78-86%, highlighting its continued focus on operational performance amid challenging chemical market conditions.
E’s Price Performance, Valuation & Estimates
Eni shares have gained 43.1% over the past year compared with the industry’s 35.4% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, E trades at a trailing 12-month enterprise-value-to-EBITDA (EV/EBITDA) of 6.84X. This is higher than the broader industry average of 5.35X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for E's 2026 earnings has remained constant over the past seven days.
Image Source: Zacks Investment Research
E currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.